FP6Individual fellowship2005–2007

VAP1 IN ARTERIES · Role of VAP-1/SSAO in arterial wall physiology

FP6 — Marie Curie Actions (Human Resources and Mobility)

Duration
2005-05-01 → 2007-04-30
EU contribution
€164,267
Participants
1
Scheme
EIF

Lines connect the coordinator with its partners.

Results in brief

Final Activity Report Summary - VAP1 IN ARTERIES (Role of VAP-1/SSAO in arterial wall physiology)

Arterial function is to absorb the variations of the arterial blood pulse pressure at the heart and to transform it into a continuous blood flow. Because changes in the organisation and composition of the arterial wall can have consequences on its mechanical properties and lead to aneurysms, dissections and ruptures, it is important to understand how proteins interact together. The most important proteins forming this matrix are elastin and collagen. Until now, the lysyl oxidase (LO) is the principal enzyme establishing links in or between elastin and collagen. But recently, another enzyme was suspected to be involved in these processes. This enzyme is called 'vascular adhesion protein-1' (VAP-1) or 'semicarbazide-sensitive amine oxidase' (SSAO) and produces molecules highly reactive and harmful. Its functions are not well understood yet. The goal of this project was to evaluate the role of this enzyme in the arterial wall using mice lacking VAP-1 / SSAO (SSAO-/- mice), recently established by Jalkanen's group. This was the first functional study of arteries lacking SSAO. Neither the arterial blood pressure nor the mechanical properties (stiffness and the mechanical strength) of large arteries in SSAO-/- mice were modified compared to wild type mice. Nevertheless, the diameter of the carotid artery was significantly higher in SSAO-/- mice suggesting that VAP-1/SSAO might contribute to arterial remodeling which occurs in some human aneurismal diseases. The morphology of the elastin network, the elastin and collagen content were identical in the two groups. The contraction and dilatation properties of arteries were unchanged in SSAO-/- mice. No change in aortic lysyl oxidase (LO) activity was detectable, indicating that SSAO invalidation is not accompanied by a compensatory increase in LO activity. Elastin does not seem to be oxidised by SSAO. Our results indicate that the lack of SSAO in mice modifies arterial geometry but does not influence mechanical properties. However, these results argue against the hypothesis that SSAO interferes in elastic fibre organisation, elastin cross-linking processes and vasoreactivity. The microarray analysis shows that some genes coding for lipid metabolism, immunity system and endothelial factors were modified suggesting that the lack of VAP-1/SSAO might protect against the development of atherosclerosis and this proposal gave rise to new research. To assess better this question, we mated APOE mice prone to develop atherosclerosis with SSAO-/- mice to generate APOE SSAO-/- mice. We hope soon to be able to answer the following question: does the absence of SSAO reduce the development of atherosclerosis in APOE mice?

Data: CORDIS, © European Union

Project objective

Because changes in the organization and composition of extra-cellular matrix can have consequences on mechanical properties of the arterial wall, understand mechanisms of maturation of the elastin and collagen, (maines extra-cellular proteins) is important.Vascular smooth muscle cells highly express vascular adhesion protein 1 (VAP-1), which display a semicarbazide-amine oxidase (SSAO) activity. Studies using pharmacological inhibitors of SSAO have been previously suggested that SSAO could be important for the arterial wall organization, without excluding that a part of the affects was due to lysyl oxidase inhibition. Lysyl oxydase is the main enzyme establishing cross-links in or between elastin and collagan until now.So I will study tha SSAO role in arterial wall, comparing arteries from wild type, VAP-1 knockout mice (establishment by the host) and VAP-1 knouckhout mice over-expressing VAP-1 in smooth muscles (will established during this project).Histomorphometry and immunohistochemistry will be used to evaluate the arterial morphology and organization, content in elastin and collagen will also be measured. Arterial mechanical properties will be evaluated in vivo with eckotracking and mechanical resistance will be tested in vitro with the collaboration of Lacolley's laboratory. Moreover, because endogenous substrate of VAP-1/SSAO are not known, I will search whether SSAO from vascular smooth muscle cells is able to oxidize directly amine moiety in elastin and collagen to cross-link these molecules.Then, I will verify whether SSAO activity can regulate vascular smooth muscle cells phenotype and expression of extra-cellular matrix proteins. VAP-1/SSAO expression will be measured in function of quality and quantity of extra-cellular matric

Original text from CORDIS.

Participants

  • UNIVERSITY OF TURKU · TurkuCoordinatorFinland

Links

Data: CORDIS, © European Union